Private Equity

Updated:

MacAndrews & Forbes Holdings

Ronald Perelman's wholly-owned holding company operates biotech and financial-services businesses with permanent capital — no fund structures, no LPs.

MacAndrews & Forbes Holdings

Our core strategy is to focus our business lines on strong market positions, high quality management with vertical expertise, recognized grow

General information

Firm type

Private Equity

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

New York

Corporate office

31 East 62nd Street, New York, NY 10065, United States

Principals

Ronald O. Perelman

Chairman and Chief Executive Officer

Sector focus

FinTechBiotechnologyHealthcare ServicesIndustrial Tech

Frequently asked questions

Who runs investment decisions at MacAndrews & Forbes?

Ronald O. Perelman, as Chairman and CEO, is the ultimate decision-maker for all acquisitions and divestitures. The firm operates as his personal holding company, making his conviction the sole driver of the portfolio. The website references a management team that supports operations, but executive names and titles beyond Perelman are not publicly listed.

Is MacAndrews & Forbes a traditional private equity fund?

No. It is a wholly-owned holding company that deploys Ronald Perelman's personal capital without limited partners or a fixed fund life. This permanent-capital structure allows it to hold businesses indefinitely and sustain companies through long regulatory or development cycles, as seen with SIGA Technologies and vTv Therapeutics.

Does MacAndrews & Forbes invest in funds or only directly into companies?

The firm's public disclosures describe only direct ownership of a small number of operating businesses. There is no mention of making fund commitments to external managers, investing in third-party private equity funds, or participating in club deals alongside other investors.

What investment stages does MacAndrews & Forbes target?

The firm acquires established businesses and also maintains controlling interests in early- to clinical-stage biotechnology companies. Vericast represents a mature, revenue-generating financial-services platform, while vTv Therapeutics remains clinical-stage. This blend of cash-flowing assets and development-stage biotech is an atypical mix for a personal holding company.

How does MacAndrews & Forbes source deals?

The firm's deal sourcing is not publicly documented, but its limited number of holdings suggests a relationship-driven, opportunistic approach. The long-term, concentrated bets — particularly the decades-long relationship with U.S. government biodefense contracting through SIGA — indicate sourcing based on Perelman's networks and willingness to navigate complex regulatory landscapes.

Where does the underlying wealth come from?

Ronald O. Perelman's wealth originates from decades of leveraged buyouts and corporate control investing, including historic transactions involving Revlon, Marvel Entertainment, and Scientific Games. MacAndrews & Forbes is the current entity that holds his personal portfolio of operating companies.

Does the firm maintain separate philanthropic structures?

The MacAndrews & Forbes website does not reference a philanthropic foundation or giving vehicles. Perelman's charitable activities, including significant gifts to medical and educational institutions, are conducted through personal or family entities that are structurally separate from the holding company.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More New York Private Equity profiles